Editas Medicine (EDIT) Non-Current Debt (2016 - 2025)
Editas Medicine's (EDIT) quarterly Non-Current Debt came in at $53.6 million in Q4 2025, up 2.23% year-on-year from $52.4 million in Q4 2024, and down 0.86% on a QoQ basis from $54.1 million in Q3 2025.
Editas Medicine (EDIT) Non-Current Debt (2016 - 2025) Analysis & Trends
Editas Medicine (EDIT) has 4 years of Non-Current Debt data on file, last reported at $53.6 million in Q4 2025.
- On a quarterly basis, Non-Current Debt rose 2.23% year-over-year to $53.6 million in Q4 2025; TTM through Dec 2025 was $53.6 million, a 2.23% increase from a year earlier, with the FY2025 full-year figure at $53.6 million, up 2.23% from the prior year.
- Non-Current Debt for Q4 2025 stood at $53.6 million, down from $54.1 million in the prior quarter.
- Over the last five years, Non-Current Debt for EDIT reached as high as $54.1 million in Q3 2025 and fell as low as $49.6 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 105.94 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 842.92 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.99 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Editas Medicine | 245.95 Mn | 99.30 Mn | - | 53.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 53.61 Mn |
| Sep 30, 2025 | 54.07 Mn |
| Jun 30, 2025 | 51.67 Mn |
| Mar 31, 2025 | 49.58 Mn |
| Dec 31, 2024 | 52.43 Mn |
| Dec 31, 2017 | 7.50 Mn |
| Jun 30, 2017 | 15.00 Mn |
| Mar 31, 2017 | 15.00 Mn |
| Dec 31, 2016 | 10.00 Mn |